…ACD856, the lead clinical drug candidate in the NeuroRestore platform, exhibits antidepressant effects in various preclinical models. The drug works by stimulating specific signalling pathways in the central nervous system…
Rejuvenate Biomed, a clinical-stage company advancing therapeutics to delay the onset of age-related diseases, has completed a six-week clinical proof-of-mechanism study with lead candidate RJx-01 for the treatment of sarcopenia….
Aulos Bioscience has revealed new safety and efficacy data from the Phase I dose escalation portion of its Phase I/II clinical trial of AU-007 in patients with unresectable locally advanced…
…Syndrome Therapeutics (FAST). The grant is intended to support the entire trajectory of drug development – from the proof-of-concept studies through to the IND-enabling studies required for a clinical trial…
…whose disease has progressed on Tagrisso,” said Rodney Varner, Chairman, President and Chief Executive Officer at Genprex. “In addition, the preclinical data presented by our research collaborators is very encouraging,…
…considerably lower doses of radiation, meaning more patients, including children, can participate in clinical trials. NPIP’s network of infrastructure and intelligence will also connect insights from many research programmes and…
…nanocarriers, antibody drug conjugates – can help address unmet need in oncology. It will include Spiro Rombotis, CEO, Cyclacel, a clinical-stage biopharmaceutical company developing innovative cancer medicines, Joseph R Peterson,…
…that the therapy can postpone disease progression in advanced CTCL. The RESMAIN study is one of the largest randomised controlled clinical trials in advanced CTCL, involving more than 50 clinical…
…since 2005, of which 13 have reached clinical trials. In 2021 the ICR formally opened a new £70m building on its site in Sutton, South London, which now houses around…
…during the progression from preclinical to formulation optimisation and clinical trials. Download this new guide from SGS to discover: How to collaborate in the fast-paced world of drug development The…
…inflammatory responses and increased protein production, Karikó and Weissman had eliminated critical obstacles on the way to clinical applications of mRNA. Read DDW’s In-Focus eReport to find out more about…
…been granted clinical trial authorisation by the UK’s MHRA to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid…
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Calliditas Therapeutics for the treatment of Alport syndrome with setanaxib. Based on supportive pre-clinical work, Calliditas…
…such as cancers and to identify novel therapies and repurpose existing therapies across the company’s eight lead candidates that are undergoing preclinical or clinical evaluation. Quris-AI – combines patient-on-a-chip, AI…
…gene therapy switch suppliers midstream in clinical development? What are the costs and time delays of switching suppliers later in clinical development? How will not having a GMP supplier impact…
…with cMET overexpression. The designation for Mythic, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, encompasses NSCLC patients with…
